33893-85-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(Hydroxymethyl)cyclohexanol (cisand transmixture) is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its ability to undergo multiple chemical reactions, enabling the creation of a diverse range of medicinal products with different therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(Hydroxymethyl)cyclohexanol (cisand transmixture) serves as a crucial building block for the development of agrochemicals, contributing to the production of effective and innovative products for agricultural applications.
Used in Organic Synthesis:
4-(Hydroxymethyl)cyclohexanol (cisand transmixture) is utilized as a versatile intermediate in organic synthesis for the preparation of a wide array of organic compounds, leveraging its reactivity in esterification, oxidation, and reduction processes to yield compounds with varied functionalities and applications.

InChI:InChI=1/C7H14O2/c8-5-6-1-3-7(9)4-2-6/h6-9H,1-5H2

Upstream product

• 120-57-0 piperonal 
• 100-09-4 4-methoxybenzoic acid 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 64-17-5 ethanol 

Downstream Products

• 279-91-4 6-Thiabicyclo<3.2.1>octan 
• 683269-72-9 4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexanol 

Relevant academic research and scientific papers

MOF-derived hcp-Co nanoparticles encapsulated in ultrathin graphene for carboxylic acids hydrogenation to alcohols

Highly efficient conversion of carboxylic acids to valuable alcohols is a great challenge for easily corroded non-noble metal catalysts. Here, a series of few-layer graphene encapsulated metastable hexagonal closed-packed (hcp) Co nanoparticles were fabricated by reductive pyrolysis of metal-organic framework precursor. The sample pyrolyzed at 400 °C (hcp-Co@G400) presented outstanding performance and stability for converting a variety of functional carboxylic acids and its turnover frequency was one magnitude higher than that of conventional facc-centered cubic (fcc) Co catalysts. In situ DRIFTS spectroscopy of model reaction acetic acid hydrogenation and DFT calculation results confirm that carboxylic acid initially undergoes dehydroxylation to RCH2CO* followed by consecutive hydrogenation to RCH2CH2OH through RCH2COH*. Acetic acid prefers to vertically adsorb at hcp-Co (0 0 2) facet with a much lower adsorption energy than parallel adsorption at fcc-Co (1 1 1) surface, which plays a key role in decreasing the activation barrier of the rate-determining step of acetic acid dehydroxylation.

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

TRICYCLIC MODULATORS OF TNF SIGNALING

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS

The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Synthesis of epibatidine analogues having a 2-substituted 2-azabicyclo[2.2.2]octane skeleton

The synthesis of 1-cyano-2-aza-[2.2.2]bicyclooctanes has been studied using the dynamic cyanide addition to cyclohexanone derivatives. These compounds were further elaborated into a new class of epibatidine derivatives from which a number of examples were

Synthesis of Epibatidine Analogues Having a 2-Substituted 2-Azabicyclo[2.2.2]octane Skeleton

The synthesis of 1-cyano-2-aza-[2.2.2]bicyclooctanes has been studied using the dynamic cyanide addition to cyclohexanone derivatives. These compounds were further elaborated into a new class of epibatidine derivatives from which a number of examples were

COMPOUND CONTAINING BASIC GROUP AND USE THEREOF

The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.